Systematic review of model-based analyses reporting the cost-effectiveness and cost-utility of cardiovascular disease management programs

European Journal of Cardiovascular Nursing

Volumn 14, Issue 1, 2015, Pages 26-33

  Maru, Shoko ^a   Byrnes, Joshua ^a   Whitty, Jennifer A ^a   Carrington, Melinda J ^b   Stewart, Simon ^b   Scuffham, Paul A ^a  

^a GRIFFITH UNIVERSITY   (Australia)

^b BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

Author keywords

Cardiovascular disease; cost effectiveness; disease management; economic evaluation; Markov model

Indexed keywords

CARDIOVASCULAR DISEASE; CARDIOVASCULAR DISEASE MANAGEMENT PROGRAM; CEREBROVASCULAR ACCIDENT; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; ECONOMIC EVALUATION; HEALTH CARE SYSTEM; HEALTH PROGRAM; HEART FAILURE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; CARDIOVASCULAR DISEASES; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; ECONOMICS; FEMALE; HEALTH CARE COST; MALE; META ANALYSIS; ORGANIZATION AND MANAGEMENT; OUTCOME ASSESSMENT; PATIENT CARE; PROBABILITY; PROCEDURES; UNITED STATES;

CARDIOVASCULAR DISEASES; COST-BENEFIT ANALYSIS; FEMALE; HEALTH CARE COSTS; HUMANS; MALE; MARKOV CHAINS; OUTCOME ASSESSMENT (HEALTH CARE); PATIENT CARE MANAGEMENT; UNITED STATES;

EID: 84920972650     PISSN: 14745151     EISSN: 18731953     Source Type: Journal    
DOI: 10.1177/1474515114536093     Document Type: Review

References (46)

1. Nolte E, McKee M Caring for people with chronic conditions: A health system perspective. Maidenhead, UK: Open University Press/McGraw Hill Education ; 2008 :
2. Graves N, Walker D, Raine R, et al. Cost data for individual patients included in clinical studies: No amount of statistical analysis can compensate for inadequate costing methods. Health Econ. 2002 ; 11: 735-739
3. Halliday RG, Darba J. Cost data assessment in multinational economic evaluations: Some theory and review of published studies. Appl Health Econ Health Policy. 2003 ; 2: 149-155
4. Conklin A, Nolte E Disease management evaluation (A comprehensive review of current state of the art). Santa Monica: The RAND Corporation ; 2010 :
5. Promoting cardiovascular health in the developing world: A critical challenge to achieve global health. Washington, DC: The National Academies Press ; 2010 :
6. Trogdon JG, Finkelstein EA, Nwaise IA, et al. The economic burden of chronic cardiovascular disease for major insurers. Health Promot Pract. 2007 ; 8: 234-242
7. Nichols M, Townsend N, Luengo-Fernandez R, et al European Cardiovascular Disease Statistics 2012. Brussels: European Heart Network; Sophia Antipolis: European Society of Cardiology ; 2012 :
8. Australia's health 2012. Canberra: Australian Institute of Health and Welfare ; 2012 :
9. Ofman JJ, Badamgarav E, Henning JM, et al. Does disease management improve clinical and economic outcomes in patients with chronic diseases? A systematic review. Am J Med. 2004 ; 117: 182-192
10. Zwar N, Harris M, Griffiths R, et al Research Centre for Primary Health Care and Equity, School of Public Health and Community Medicine, UNSW ; 2006 :
11. Weingarten SR, Henning JM, Badamgarav E, et al. Interventions used in disease management programmes for patients with chronic illness-which ones work? Meta-analysis of published reports. BMJ. 2002 ; 325: 925
12. Moher D, Liberati A, Tetzlaff J, et al. Preferred Reporting Items for Systematic reviews and Meta-Analyses: The PRISMA statement. PLoS Med. 2009 ; 6 :
13. Norris SL, Glasgow RE, Engelgau MM, et al. Chronic disease management: A definition and systematic approach to component interventions. Dis Manage Health Outcomes. 2003 ; 11: 477-488
14. Krumholz HM, Currie PM, Riegel B, et al. A taxonomy for disease management: A scientific statement from the American Heart Association Disease Management Taxonomy Writing Group. Circulation. 2006 ; 114: 1432-1445
15. Campbell and Cochrane Economics Methods Group and the Evidence for Policy and Practice Information and Coordinating Centre. CCEMG - EPPI-Centre Cost Converter (v.1.3), http://eppi.ioe.ac.uk/costconversion/default.aspx) (accessed August 2013) 2010.
16. Shemilt I, Thomas J, Morciano M. A web-based tool for adjusting costs to a specific target currency and price year. Evidence Policy. 2010 ; 6: 51-59
17. HestonASummersRAtenB. Penn World Table Version 7.1, Center for International Comparisons of Production, Income and Prices at the University of Pennsylvania, Nov2012. https://pwt.sas.upenn.edu/ (accessed May 2013).
18. Chiou C, Hay J, Wallace J, et al. Development and validation of a grading system for the quality of cost-effectiveness studies. Med Care. 2003 ; 41: 32-44
19. Husereau D, Drummond M, Petrou S, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) - Explanation and elaboration: A report of the ISPOR Health Economic Evaluations Publication Guidelines Task Force. Value Health. 2013 ; 16: 231-250
20. Wade V, Karnon J, Elshaug A, et al. A systematic review of economic analyses of telehealth services using real time video communication. BMC Health Serv Res. 2010 ; 10: 233
21. Ligthart S, Vlemmix F, Dendukuri N, et al. The cost-effectiveness of drug-eluting stents: A systematic review. CMAJ. 2007 ; 176: 199-205
22. Datta SK, Oddone EZ, Olsen MK, et al. Economic analysis of a tailored behavioral intervention to improve blood pressure control for primary care patients. Am Heart J. 2010 ; 160: 257-263
23. Gillespie P, O'Shea E, Murphy AW, et al. The cost-effectiveness of the SPHERE intervention for the secondary prevention of coronary heart disease. Int J Technol Assess Health Care. 2010 ; 26: 263-271
24. Gillespie P, O'Shea E, Murphy AW, et al. Relative cost effectiveness of the SPHERE intervention in selected patient subgroups with existing coronary heart disease. Eur J Health Econ. 2012 ; 13: 429-443
25. Jafar TH, Islam M, Bux R, et al. Cost-effectiveness of community-based strategies for blood pressure control in a low-income developing country: Findings from a cluster-randomized, factorial-controlled trial. Circulation. 2011 ; 124: 1615-1625
26. Mason JM, Freemantle N, Gibson JM, et al. Specialist nurse-led clinics to improve control of hypertension and hyperlipidemia in diabetes: Economic analysis of the SPLINT trial. Diabetes Care. 2005 ; 28: 40-46
27. Miller G, Randolph S, Forkner E, et al. Long-term cost-effectiveness of disease management in systolic heart failure. Med Decis Making. 2009 ; 29: 325-333
28. Perman G, Rossi E, Waisman GD, et al. Cost-effectiveness of a hypertension management programme in an elderly population: A Markov model. Cost Eff Resour Alloc. 2011 ; 9: 4
29. Moertl D, Steiner S, Coyle D, et al. Cost-utility analysis of nt-probnp-guided multidisciplinary care in chronic heart failure. Int J Technol Assess Health Care. 2013 ; 29: 3-11
30. Yu J, Shah BM, Ip EJ, et al. A Markov model of the cost-effectiveness of pharmacist care for diabetes in prevention of cardiovascular diseases: Evidence from Kaiser Permanente Northern California. J Manag Care Pharm. 2013 ; 19: 102-114
31. Hay JW, Smeeding J, Carroll NV, et al. Good research practices for measuring drug costs in cost effectiveness analyses: Issues and recommendations: The ISPOR Drug Cost Task Force report - Part I. Value Health. 2010 ; 13: 3-7
32. Ramsey S, Willke R, Briggs A, et al. Good research practices for cost-effectiveness analysis alongside clinical trials: The ISPOR RCT-CEA Task Force report. Value Health. 2005 ; 8: 521-533
33. Franco OH, Peeters A, Bonneux L, et al. Blood pressure in adulthood and life expectancy with cardiovascular disease in men and women: Life course analysis. Hypertension. 2005 ; 46: 280-286
34. Reed SD, Li Y, Kamble S, et al. Introduction of the Tools for Economic Analysis of Patient Management Interventions in Heart Failure Costing Tool: A user-friendly spreadsheet program to estimate costs of providing patient-centered interventions. Circ Cardiovasc Qual Outcomes. 2012 ; 5: 113-119
35. Buxton MJ, Drummond MF, Van Hout BA, et al. Modelling in economic evaluation: An unavoidable fact of life. Health Econ. 1997 ; 6: 217-227
36. Drummond MF, Sculpher MJ, Torrance GW, et al Methods for the economic evaluation of health care programmes. 2005. 3rd edition. New York: Oxford University Press, 2005. New York: Oxford University Press ; 2005 2005 :
37. Neumann PJ, Greenberg D, Olchanski NV, et al. Growth and quality of the cost-utility literature, 1976-2001. Value Health. 2005 ; 8: 3-9
38. Serxner S, Baker K, Gold D. Guidelines for analysis of economic return from health management programs. Am J Health Promot. 2006 ; 20: 1-17
39. Elissen A, Duimel-Peeters I, Spreeuwenberg C, et al DISMEVAL. Developing and validating disease management evaluation methods for European healthcare systems. Final report. Nolte E Hinrichs S, ed. Santa Monica, CA: RAND Corporation and DISMEVAL Consortium ; 2012 :
40. Linden A, Adler-Milstein J. Medicare disease management in policy context. Health Care Financ Rev. 2008 ; 29: 1-11
41. Nolte E, Conklin A, Adams JL, et al Evaluating chronic disease management. Santa Monica: RAND Corporation ; 2012 :
42. Pamela SW, Frances SM, Alan H, et al. Systematic review of cost effectiveness studies of telemedicine interventions. BMJ. 2002 ; 324: 1434-1437
43. Clark AM, Savard LA, Thompson DR. What is the strength of evidence for heart failure disease-management programs?. J Am Coll Cardiol. 2009 ; 54: 397-401
44. Riegel B, Lee CS, Sochalski J. Developing an instrument to measure heart failure disease management program intensity and complexity. Circ Cardiovasc Qual Outcomes. 2010 ; 3: 324-330
45. Lau J, Ioannidis JP, Terrin N, et al. The case of the misleading funnel plot. BMJ. 2006 ; 333: 597-600
46. Terrin N, Schmid CH, Lau J. In an empirical evaluation of the funnel plot, researchers could not visually identify publication bias. J Clin Epidemiol. 2005 ; 58: 894-901